Combination treatment of chemoresistant cancers
AssigneeThe Regents of the University of California
InventorsThomas Kipps, Suping Zhang, Emanuela M. Ghia
Life of this patent
Estimating the term…
Abstract
There are provided, inter alia, compositions and methods for treatment of chemoresistant cancer (breast cancer). The methods include administering to a subject in need a therapeutically effective amount of a chemotherapeutic agent and a ROR-1 antagonist. Further provided are pharmaceutical compositions including chemotherapeutic agent, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the chemotherapeutic agent is paclitaxel and the ROR-1 antagonist is cirmtuzumab.
Claims15
A method of treating a chemoresistant cancer in a subject in need thereof, said method comprising administering to said subject a therapeutically effective amount of paclitaxel or docetaxel and a therapeutically effective amount of a tyrosine kinase-like orphan receptor 1 (ROR-1) antagonist antibody, thereby treating the chemoresistant cancer in said subject, wherein the chemoresistant cancer is paclitaxel resistant or docetaxel resistant and is Her2 negative, wherein said subject is receiving or has received chemotherapy, and
- wherein said antibody comprises a humanized heavy chain variable region and a humanized light chain variable region, wherein said humanized heavy chain variable region comprises the sequences set forth in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3;
- and wherein said humanized light chain variable region comprises the sequences set forth in SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
Dependencies are inferred from the claim text.